Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation (Tables)

v2.4.0.6
Share-based compensation (Tables)
3 Months Ended
Oct. 31, 2012
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

 

 

 

 

 

 

 

 

 

 

Three months ended
October 31,

 

 

 

2012

 

2011

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

2

 

$

2

 

Research and development

 

 

1

 

 

3

 

Selling, general and administrative

 

 

139

 

 

208

 

 

 

   

 

   

 

 

 

$

142

 

$

213

 

 

 

   

 

   

 

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] A summary of the activity relating to the Company’s stock option plans for the three month period ended October 31, 2012 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

Options

 

Weighted
Average
Exercise Price

 

Aggregate
Intrinsic Value

 

 

 

 

 

 

 

 

 

Outstanding at July 31, 2012

 

 

736,490

 

$

14.50

 

$

 

 

 

 

 

 

 

 

 

   

 

Exercised

 

 

 

 

 

 

 

 

Cancelled

 

 

(50,638

)

$

11.25

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Outstanding and exercisable at end of period

 

 

685,852

 

$

14.74

 

$

 

 

 

   

 

 

 

 

   

 

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] A summary of the activity pursuant to the Company’s restricted stock awards for the three months ended October 31, 2012 is as follows:

 

 

 

 

 

 

 

 

 

 

Awards

 

Weighted
Average
Award Price

 

 

 

 

 

 

 

Unvested at July 31, 2012

 

 

257,583

 

$

3.58

 

Awarded

 

 

30,000

 

$

1.52

 

Vested

 

 

(500

)

$

(3.93

)

Forfeited

 

 

(3,292

)

$

(5.13

)

 

 

   

 

   

 

Unvested at end of period

 

 

283,791

 

$

3.34